Abstract: On 15 July 2020 was the 15th anniversary of the Science Magazine issue that reported three trypanosomatid genomes, namely Leishmania major, Trypanosoma brucei, and Trypanosoma cruzi. That publication was a milestone for the research community working with trypanosomatids, even more so, when considering that the first draft of the human genome was published only four years earlier after 15 years of research. Although nowadays, genome sequencing has become commonplace, the work done by researchers before that publication represented a huge challenge and a good example of international cooperation. Research in neglected diseases often faces obstacles, not only because of the unique characteristics of each biological model but also due to the lower funds the research projects receive. In the case of Trypanosoma cruzi the etiologic agent of Chagas disease, the first genome draft published in 2005 was not complete, and even after the implementation of more advanced sequencing strategies, to this date no final chromosomal map is available. However, the first genome draft enabled researchers to pick genes a la carte, produce proteins in vitro for immunological studies, and predict drug targets for the treatment of the disease or to be used in PCR diagnostic protocols. Besides, the analysis of the T. cruzi genome is revealing unique features about its organization and dynamics. In this work, I briefly summarize the actions of Latin American researchers that contributed to the first publication of the T. cruzi genome and discuss some features of the genome that may help to understand the parasite’s robustness and adaptive capabilities.

Keywords: Trypanosoma cruzi; genome; parasite; neglected diseases

1. Chagas, the Disease

Chagas disease or American trypanosomiasis is considered a zoonosis caused by the flagellate Trypanosoma cruzi. The parasite has a wide range of mammalian hosts and insect vectors of the Triatominae family. According to the WHO [1,2], there are around 6 to 10 million people affected by the disease and 12,000 deaths per year, and due to migration, the disease is now present in non-endemic countries of Europe, Canada, and Australia. Infected patients can transition from an acute infection to a chronic and often lethal phase of the disease. Hitherto, however, the only drugs widely used to treat the disease are nifurtimox and benznidazole, which are very effective, when given at the early stages of the infection. Non-vectorially transmitted infections, such as oral or congenital, present new challenges for treatment [3], and the great variability of T. cruzi surface antigens has precluded the development of effective vaccination.

Trypanosoma cruzi populations are complex and using molecular markers seven distinct taxonomic units (DTUs) [4] have been reported, out of which two, namely DTU V and VI are hybrids. However, its population dynamic is currently a subject of debate [5].
2. The Years before the 2005 Publication, a Brief Description of Latin America’s (LA) Participation in the Sequencing of the Trypanosoma cruzi Genome

When the sequencing of the human genome [6] was proposed, funding agencies and the public showed serious concerns about the sizable funds dedicated to this task when more urgent needs were not properly funded [7–9]. These concerns, when applied to the genome of pathogens causing neglected diseases, are magnified. For basic researchers working on Chagas disease, it was evident that despite many years of biochemical, clinical, epidemiological and immunological studies, no new tools for the diagnostic or treatment of the disease were available, and the successful vector control measurements implemented in Latin America South-Cone countries were not as successful when applied to sylvatic environments where Reduvii bugs are not limited to domestic environments [10]. Hence, what makes Trypanosoma cruzi such a difficult organism to control or eliminate? Is the key to answering all these problems in its genome?

Without sharing the reductionist view held by some proponents of the Human Genome Project Initiative (HGP) [6,11], that the key to understanding all genetic diseases was in the genome, LA researchers decided to launch a Trypanosoma cruzi genome initiative [12] hoping to piggyback on the successful Brazilian Xylella fastidiosa genome project [13]. This initiative was justified, having in mind the following arguments: the training of young LA scientists in the emerging technologies of genomics and bioinformatics and preparing them to take advantage of public databases to foster innovation.

Second, to achieve a better understanding of this parasite whose infestations negatively impact LA society. Third, to facilitate molecular biology studies in T. cruzi by providing a draft sequence that any laboratory could use to develop diagnostic tools or discover new therapeutic targets.

In 1993, Dr. Mariano Levin of INGEBI, Buenos Aires, proposed one of the first genome projects for T. cruzi to the Biotechnology Program III of the Ibero American Science and Technology Program (CYTED). CYTED sponsored meetings bringing together molecular biologists from Spain, Sweden, and LA to design a strategy to sequence the genome [10,14]. Later, the WHO made a call for trypanosomatid genome research, and in 1994 on the premises of the Fundacao Oswaldo Cruz in Rio de Janeiro, Brazil, the most important meeting on Trypanosomatidae genome research took place [15]. For the occasion researchers from all over the world working on trypanosomatids converged to discuss a genome sequencing strategy for some of the most important pathogens of the Trypanosomatidae family, namely Leishmania, Trypanosoma brucei, and Trypanosoma cruzi. As an outcome, Leishmania major, Trypanosoma brucei, and Trypanosoma cruzi strain CL Brener (CLB) were selected as model species for genome projects. Furthermore, a more extended network led by Carlos Frasch of San Martin University, Argentina, was created including researchers from Sweden, the US, the UK, and France [16]. The approach to sequence the T. cruzi genome was the chromosome-by-chromosome or map-as-you-go strategy of the Human Genome Project (HGP) [6]. The work was divided among participant laboratories using the limited funding of local agencies. In three years, the laboratories constructed genome libraries either from DNA (genomic libraries) or mRNA (expression libraries). The work of these early years generated important information about the CLB genome, such as (i) the electrokaryotype profile revealing a large number of chromosomal bands and homologous chromosomes presenting size polymorphisms, and extra-numbers (aneuploidy) [17,18]; (ii) large non-syntenic zones of the genome containing multigene families e.g., the trans-sialidases gene family [19]; (iii) numerous putative transposons [20,21]; (iv) the mapping and expression of important infectivity genes; (v) and that T. cruzi telomeres and subtelomeres were enriched in transposon sequences and members of other large gene families [22]. When these actions were well underway, the initiative was confronted with the hard reality of the DNA sequencing costs at that time. The cost of the $3 \times 10^9$ bp human genome was calculated to be between 500 million to 1 billion USD. Taking as a reference the HGP lower estimate, for the CLB $\sim6 \times 10^7$ bp genome the approximate cost was 20 million USD. Fortunately for L. major and T. brucei the Welcome Trust provided support for these projects, whereas T. cruzi received no funding. A simplistic approach for T. cruzi was to develop end-linking maps with bacterial artificial...
chromosomes (BACs) or Yeast artificial chromosomes (YACS) recombinants (and assume that, given the taxonomical proximity to *T. brucei*, the gaps could be closed using the *T. brucei* synteny information. The work for the CLB genome continued using the original strategy until Dr. Najib El Sayed of the Institute for Genomic Research (TIGR), teaming up with colleagues of the Karolinska Institute (Sweden) and Seattle Biomedical Research Institute (USA), sequenced the whole *T. cruzi* genome using the Whole Genome Shotgun (WGS) approach developed by Venter [11] for the alternative human genome project. This approach consists of the random cloning of DNA fragments to generate libraries with different fragment sizes, and then carry out an automated computer assembly. Through WGS, the first draft of the CLB genome was accomplished in record time, the rest of the participant laboratories engaged in gene annotation and mapping their contigs and clones on this raw draft.

3. A Brief Description of the Initial Findings in the CLB Genome

With the 2005 publication of the first draft [23], scientists realized how complex the *T. cruzi* genome was; the automated annotations revealed a much higher degree of sequence repetitions, including large multigene families, out of which the Mucin Associated Surface Protein (MASP) family was detected for the first time. Repeated sequences comprised about half of the total genome. These repetitions often caused the collapse of the automatic assembling. Even though the CLB genome was diploid, it turned out to be a hybrid of two *T. cruzi* strains, namely Esmeraldo and non-Esmeraldo. In the current taxonomical classification, CLB is included in the hybrid DTU VI [4,23]. Despite all these obstacles, syntenic groups were assembled, confirming previous studies [19] about the lack of synteny for some surface protein genes. Although a final assembly was not achieved, the genome draft presented non-syntenic blocks or islands containing highly repeated genes and blocks made up of simple genes interrupted by a few copies of retrotransposons and genes from surface protein families. At the start of each syntenic block, there were breakpoints made up of simple repeated sequences being the origins of the bidirectional polycistrionic transcription.

Similar to *T. brucei*, *T. cruzi* had a large number of transposons and transposon-associated sequences, but in *T. cruzi* the non-LTR transposons have the potential to be functional [24,25], and there is no RNAi machinery to control their activities.

The subtelomeres were confirmed as complex and different among all Trypanosmatids [24,26], and in the case of CLB they were non-syntenic and often enriched in highly repeated sequences.

A comparative analysis with the *L. major* and *T. brucei* genomes revealed that 32% of *T. cruzi* proteins were species-specific [23]. Another interesting feature was the expansion of the kinome (body of kinases), and the presence of enzymes necessary for meiotic recombination. Surprisingly, important genes for end joining non-homologous recombination (EJNHR) were missing in the three typanosomatids sequenced [24]. One the major contributions of the 2005 genome draft was that for the first time a large scale integration of *T. cruzi* metabolism networks was made possible, which opened the way for whole proteome analysis [27,28] and the application of system biology approaches [29].

4. What is New and What is Challenging

Even today, despite the refinements of new sequencing and bioinformatics technologies we still do not have a solid *T. cruzi* chromosomal map and considering the heterogeneity and genome variability of *T. cruzi* populations, we might never have one. Perhaps, a less noisy view of the *T. cruzi* genome could be obtained by single-cell genome sequencing [30–32]. So far, it seems that the best chromosomal map assembled for CLB was obtained by Weatherly et al. (2009) [33] using the information from the parental strains of the two haplotypes that make up the CLB genome, and closing the gaps with the synteny information derived from other trypanosomes, and/or BAC end joining. These authors defined 41 pairs of chromosomes as well as two artificially assembled contigs that could not be assigned at any chromosome. More recently, through long sequence reads obtained by the PACBio technology several laboratories have succeeded in closing some of the gaps in the original genome draft [30,34–38].
Despite not having a firm chromosomal map, the availability of the original genome blueprint, plus the speed and affordability of current DNA sequencing techniques, the genomes from all DTUs (distinct taxonomic units or near-clades) have been sequenced, and population analysis is now being done with whole genomes instead of isolated makers. The comparative analyses of T. cruzi isolates have shown variations in gene copy numbers and aneuploidy not only between the DTUs but also within DTUs from sympatric geographic areas [30,39]. Using the same tools, sexual recombination and parasexual hybrid formation have been detected in some T. cruzi populations [37,39–42].

Aneuploidy and variable gene copy numbers of genes [30,42,43] are at the base of the expansion of important genes for infecting and evading the host’s immune system, such as surface proteins, glycosidases, amastins, and GP63 proteases [44,45]. Aneuploidy, a condition that in other eukaryotes causes cell growth retardation [46], does not seem problematic for T. cruzi, and likewise, in Candida glabrata [47] an increase in gene dosage may serve as a dynamic mechanism to generate variability for adaptive purposes. Although there is the possibility that T. cruzi aneuploids are laboratory artifacts, aneuploids have been found in clones from non-aneuploid sympatric populations [30].

Copy Number Variations [3,34,35,37,38,44–50] originated by gene duplication, ectopic recombination, unequal-crossing-over, gene mobilization via transposons, chromosome duplications, and others, may contribute to variants with a selective advantage. As stated before, T. cruzi’s genes coding for surface proteins are notably expanded [30,34–36,49,50] and some variants have already been adapted to processes related to the infectivity and interaction with the host [51–54]. In addition to complete genes, the T. cruzi genome harbors an enormous repertoire of pseudogenes, which could be seen as a futile waste of energy and are likely to be reservoirs for the generation of gene variants. However, another possibility is that they [55–58] act as transcription regulators [59]. One of the keys to the understanding of T. cruzi genome dynamics might reside in the role that pseudogenes might play. As mentioned, the participation of transposons and repeated sequences in shaping the T. cruzi genome is supported by their presence in regions where gene synteny is broken and polycistronic transcription starts. Furthermore, it has been suggested that transposon may provide these sites [24,60].

The characteristics of the T. cruzi genome raises some questions: how can the parasite keep its very precise form and differentiation program with a very variable genome, including many non-syntenic groups of genes? How can mitotic and meiotic mechanisms efficiently operate with extra chromosomes and non-syntenic chromosomal blocks? Finally, how can transcription processes be regulated in rearranged syntenic blocks?

The block structure of the T. cruzi genome allows the parasite to preserve in syntenic groups of polycistronic transcription the core functions (housekeeping genes) necessary for the parasite differentiation, metabolism, and division, whereas the blocks containing genes for important surface determinants display constant reshuffling generating variability. These two blocks appear to have different evolution patterns [23,34,36,37].

The generation of variability through non-sexual processes such as ectopic recombination has been experimentally assessed between T. cruzi subtelomeres [61], and given the large sequence variability registered at the subtelomeres, together with their enrichment in contingency genes such as the transialidases; transposons and transposons associated sequences seem to be important locations for the generation of variability [22,37,62,63]. The mobilization of variants may occur either by ectopic recombination and/or mediated by a transposon (gene transduction) [64,65]. In all these events homologous recombination (HR) seems to play an important role, and perhaps targeting some of the enzymes involved in HR may help to solve some of these questions.

Considering sexuality and the occurrence of meiotic processes, most genes necessary for meiotic recombination are present in T. cruzi [23], but a cytological study of meiosis is precluded, not only by the small size of the chromosomes but also by its lack of condensation and non-dissolution of the nuclear membrane during division processes. Therefore, pieces of evidence for hybridization and sexual exchanges come from the molecular mapping of genetic markers [43] and, more recently, through whole-genome analysis [30,34,39–42]. With this type of approach, researchers have accrued
pieces of evidence of sexual recombination in *T. cruzi* populations from Brazil, Peru, Ecuador, and Colombia.

A different aspect of sexual or parasexual exchanges in *T. cruzi* has to do with the inheritance of mitochondrial DNA. The kinetoplast, a DNA body common to all Kinetoplastida, is an intricate mesh of mini and maxicircles; the former participate in the editing process of the encrypted genes encoded in the maxicircle, which is the equivalent of the mitochondrial DNA in other organisms. There are claims of the uniparental contribution of K-DNA in parasexual hybrids [23,66] but with pieces of evidence of exchanges with other clades or DTUs. Little is known about how these inter-DTUs introgression processes occur [30,67,68].

Many questions about sexuality remain, such as when and where sexual recombination occurs? Are gametes ever produced? Are both gametes contributing with mitochondrial DNA, in which differentiation forms, and in which host does it take place?

5. Clonal or Not Clonal, is That the Question?

A panmictic evolution with sexual exchanges through gametes or parasexual fusion of cells [5,69] does not appear to contradict the general hypothesis that the *T. cruzi* population structure appears to be clonal [69,70], or as more recently coined, has a predominantly clonal signal [70]. Either way, the apparent infrequency of sexual exchanges indicates it is not obligatory for *T. cruzi*. Clonality can result from genome instability since aneuploidy and variable gene copy numbers could be obstacles for efficient meiotic recombination. However, under challenging situations, this instability can generate gene variants with adaptive advantages at a faster rate when compared to sexual recombination. This fact agrees with the low frequency of sexual recombination registered in whole genomic analysis or the limited recombination between hybrid strain chromosomes [23,34,70]. Sexual recombination has been detected mainly in closely related populations, and rarely between strains from different near-clades. Some authors claim that sexual recombination occurs more frequently but remains undetected because it happens in closely related parasites (endogamy) [40]. The key to alternatives ways of evolution may reside in the heterogeneity of *T. cruzi* populations, which even under in vitro culturing are very heterogeneous [71,72]. Within the population, some members may retain the ability for sexual exchanges, while the majority stays clonal and adapted to a given environment. The accumulation of deleterious mutations during clonal propagation may drive a cell to its death and be eliminated from the population (Muller Rachet) [73]. However, since *T. cruzi* populations do not divide synchronously, not all cells will reach this end simultaneously, and some of the survivors with fewer genome alterations or those that have reversed to the diploid [30] condition by chromosomal loss, can engage in sexual or parasexual exchanges to replenish population fitness. Although it has been suggested that sexual recombination occurs inside the vertebrate host [68], it seems to the parasite’s advantage to be able to generate variants at all stages of differentiation, as well as in all hosts, so populations can go either way, panmictic or clonal.

Genome-wise, *T. cruzi* seems to be the master of variation, a property that explains its resilience, its capacity to infect a wide range of hosts and vectors, the utilization of multiple ways of infection, its capacity to recover its karyotype after a massive Gamma ray irradiations [74], and the rapid acquisition of surface protein variants to escape the host’s immune system, a fact that makes the attainment of an effective vaccine very difficult.

6. Final Considerations

One indisputable fact is that despite the many genetic variations and polymorphisms recorded among *T. cruzi* strains, the parasite is a pathogenic entity that keeps its basic cell architecture and differentiation programs and infects humans causing Chagas disease. For practitioners, infections by *T. cruzi*, regardless of the considerations about the parasite types, are treated in the same classical way, which involves the drugs nifurtimox or benznidazol.
Nonetheless, the information provided by the 2005 publication paved the way for the generation of new diagnostic tools, the discovery of important metabolic routes, the publication of nearly 2000 research papers, and the production of a wealth of information that allows a more systemic approach to *T. cruzi* biology and a large scale search for druggable targets [75–77].

The genetic experimentation with *T. cruzi* has lagged behind *Leishmania* and *T. brucei* due to the lack of cloning vectors with inducible promoters and/or an RNAi machinery that could allow for checking the importance and function of genes, and although the recent use of CRISPR technologies has facilitated this task [78,79], we are far from what is known about *T. brucei*. A more in-depth insight into the causes of *T. cruzi* genome plasticity and genetic variability may lead to understanding how the parasite generates diversity and provide us with better tools to effectively tackle Chagas disease.

Last, but certainly not least, the Trypanosomatid genomes contributed to the generation of a new cohort of young LA researchers in genomics and bioinformatics, some of whom are currently successfully engaged in fighting other diseases.

**Funding:** This research receives no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. WHO. Chagas Disease (American Trypanosomiasis); WHO: Geneva, Switzerland, 2019. Available online: https://www.who.int/health-topics/chagas-disease#tab=tab_1 (accessed on 27 June 2020).
2. Lidani, K.C.F.; Andrade, F.A.; Bavia, L.; Damasceno, F.S.; Beltrame, M.H.; Messias-Reason, I.J.; Sandri, T.L. Chagas Disease: From Discovery to a Worldwide Health Problem. *Front. Public Health* **2019**, *7*, 166. [CrossRef] [PubMed]
3. De Noya, B.A.; Colmenares, C.; Diaz-Bello, Z.; Ruiz-Guevara, R.; Medina, K.; Muñoz-Calderón, A.; Mauriello, L.; Cabrera, E.; Montiel, L.; Losada, S.; et al. Orally-transmitted Chagas disease: Epidemiological, clinical, serological and molecular outcomes of a school microepidemic in Chichiriviche de la Costa, Venezuela. *Parasite Epidemiol. Control* **2016**, *2*, 2405–6731. [CrossRef]
4. Zingales, B. *Trypanosoma cruzi* genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis, and drug sensitivity. *Acta Trop.* **2018**, *184*, 1–52. [CrossRef] [PubMed]
5. Ramirez, J.D.; Llewellyn, M.S. Reproductive clonality in protozoan pathogens—Truth or artefact? *Mol. Ecol.* **2014**, *23*, 4195–4202. [CrossRef]
6. International Human Genome Consortium Initial. Sequencing and Analysis of the Human Genome. *Nature* **2001**, *409*, 860–921. [CrossRef] [PubMed]
7. Angier, N. Great 15′year Project to decipher Genes stirs opposition. *The New York Times. Science Times*, 15 June 1990.
8. The human Genome. *Deciphering the Blueprint of Heredity*; Cooper, N.G., Ed.; University Science Books: Mill Valley, CA, USA, 1994; ISBN 0-935702-29-6.
9. Latham, L. The failure of the genome. *The Guardian*, 17 April 2011.
10. Ramsey, J.M.; Schofield, C.J. Control of Chagas disease vectors. *Salud Publica Mex.* **2003**, *45*, 123–128. [CrossRef]
11. Venter, J.C.; Adams, M.D.; Myers, E.W.; Li, P.W.; Mural, R.J.; Smith, H.O.; Yandell, M.; Evans, C.A.; Holt, R.A.; Gocayne, J.D.; et al. The sequence of human genome. *Science* **2001**, *291*, 1304–1351. [CrossRef]
12. Degrave, W.; Levin, M.J.; Franco da Silveira, J.; Morel, C.M. Parasite Genome Projects and the Trypanosoma cruzi Genome Initiative. *Mem. Inst. Oswaldo Cruz* **1997**, *92*, 859–862. [CrossRef]
13. Simpson, A.J.; Reinach, F.C.; Arruda, P.; Abreu, F.A.; Acencio, M.; Alvarenga, R.; Alves, L.M.; Araya, J.E.; Baia, G.S.; Baptista, C.S.; et al. The Xylella fastidiosa Consortium of the Organization for Nucleotide Sequencing and Analysis The genome sequence of the plant pathogen Xylella fastidiosa. *Nature* **2000**, *406*, 151–157. [CrossRef]
14. Ferrari, I.; Lorenzi, H.; Santos, M.R.; Brandariz, S.; Requena, J.M.; Schijman, A.; Vázquez, M.; Silveira, J.F.; Ben-Dov, C.; Medrano, S.; et al. Towards the Physical Map of the Trypanosoma cruzi Nuclear Genome: Construction of YAC and BAC Libraries of the Reference Clone T. cruzi CL-Brener. *Mem. Inst. Oswaldo Cruz* **1997**, *92*, 843–852. [CrossRef]
33. Weatherly, D.B.; Boehlke, C.; Tarleton, R.L. Chromosome level assembly of the hybrid Trypanosoma cruzi genome. BMC Genom. 2009, 10, 255. [CrossRef]
34. Frazen, O.; Ochaya, S.; Sherwood, E.; Lewis, M.D.; Llewellyn, M.S.; Miles, M.A.; Anderson, B. Shotgun Sequencing Analysis of Trypanosoma cruzi I Sylvio X10/1 and comparison with T. cruzi VI CL Brener. PLoS Negl. Trop. Dis. 2011, 5, e984. [CrossRef]
35. Callejas-Hernandez, F.; Rastrojo, A.; Poveda, C.; Girones, N.; Fresno, M. Genomic assemblies of newly sequenced Trypanosoma cruzi strains reveal new genomic expansion and greater complexity. Sci. Rep. 2018, 8, 14631. [CrossRef] [PubMed]
36. Berna, L.; Rodriguez, M.; Chiribao, M.L.; Parodi-Talice, A.; Rijo, G.; Alvarez-Valin, F.; Robello, C. Expanding an expanded Genome long-read sequencing of Trypanosoma cruzi genome. Microb. Genom. 2018, 4. [CrossRef] [PubMed]
37. Talavera-Lopez, C.; Messenger, L.A.; Lewis, M.D.; Yeo, M.; Reis-Cunha, J.L.; Bartholomeu, D.C.; Calzada, J.E.; Saldaña, A.; Ramirez, J.D.; Guhl, F. Repeat-driven generation of antigenic diversity in a major human pathogen, Trypanosoma cruzi. bioRxiv 2018. [CrossRef]
38. Bradwell, K.R.; Koparde, V.N.; Matveyev, A.V.; Serrano, M.G.; Alves, J.; Parikh, H.; Huang, B.; Lee, V.; Espinoza-Alvarez, O.; Ortiz, P.A.; et al. Genomic comparison of Trypanosoma conorhini and Trypanosoma rangeli to Trypanosoma cruzi strains of high and low virulence. BMC Genom. 2018, 19, 770. [CrossRef] [PubMed]
39. Berry, A.S.F.; Salazar-Sánchez, R.; Castillo-Neyra, R.; Borрин-Mayori, K.; Chipana-Ramos, C.; Vargas-Maquera, M.; Ancca-Juarez, J.; Náquira-Velarde, C.; Levy, M.Z.; Brisson, D. Sexual reproduction in a natural Trypanosoma cruzi population. PLoS Negl. Trop. Dis. 2019, 13, e0007392. [CrossRef]
40. Lewis, M.; Llewellyn, M.S.; Yeo, M.; Acosta, N.; Gaunt, M.W.; Miles, M.A. Recent, Independent and Anthropogenic Origins of Trypanosoma cruzi Hybrids. Plos Negl. Trop. Dis. 2011, 5, e1363. [CrossRef]
41. Messenger, L.A.; Miles, M.A. Evidence and importance of genetic exchange among field populations of Trypanosoma cruzi. Acta Trop. 2015, 151, 150–155. [CrossRef]
42. Schwabl, P.; Imamura, H.; Van den Broeck, F.; Costales, J.A.; Maiguashca-Sánchez, J.; Miles, M.A.; Andersson, B.; Grijalva, M.J.; Llewellyn, M.S. Meiotic sex in Chagas disease parasite Trypanosoma cruzi. Nat. Commun. 2019, 10, 3972. [CrossRef]
43. Minning, D.; Weatherly, B.; Flibotte, S.; Tarleton, R.L. Widespread, focal copy Number variations (CNV)and whole chromosome aneuploidies in Trypanosoma cruzi Strains revealed by array comparative genomic hybridization. BMC Genom. 2011, 12, 139. [CrossRef]
44. De Pablos, L.M.; Osuna, A. Multigene Families in Trypanosoma cruzi and Their Role in Infectivity. Infect. Immun. 2012, 7, 2258–2264. [CrossRef]
45. Cardoso, M.S.; Reis-Cunha, J.L.; Bartholomeu, D.C. Evasion of the Immune Response by Trypanosoma cruzi during Acute Infection. Front. Immunol. 2016, 6, 659. [CrossRef]
46. Sheltzer, J.M.; Blank, H.M.; Pflau, S.J.; Tange, Y.; George, B.M.; Humpton, T.J.; Brito, I.L.; Hiraoka, Y.; Niwa, O.; Amon, A. Aneuploidy drives genomic instability in yeast. Science 2011, 333, 1026–1030. [CrossRef] [PubMed]
47. Polakova, S.; Blume, C.; Zárate, J.A.; Mentel, M.; Jöcksch-Ramberg, D.; Stenderup, J.; Piskur, J. Formation of new chromosomes as a virulence mechanism in yeast Candida glabrata. PNAS 2009, 106, 2688–2693. [CrossRef] [PubMed]
48. Reis-Cunha, J.L.; Rodrigues-Luiz, G.F.; Valdivia, H.O.; Baptista, R.P.; Mendes, T.A.; de Morais, G.L.; Macedo, A.M.; Bern, C.; Gilman, R.H. Chromosomal copy Number variation reveals differential levels of genomic plasticity in distinct Trypanosoma cruzi strains. BMC Genom. 2015, 16, 499. [CrossRef]
49. Briones, M.R.; Egima, C.M.; Eichinger, D.; Schenkman, S. Trans-sialidase genes expressed in mammalian forms of Trypanosoma cruzi evolved from ancestor genes expressed in insect forms of the parasite. J. Mol. Evol. 1995, 41, 120–131. [CrossRef] [PubMed]
50. Chiurillo, M.A.; Cortez, D.R.; Lima, F.M.; Cortez, C.; Ramírez, J.L.; Martins, A.G.; Serrano, M.G.; Teixeira, M.M.; da Silveira, J.F. The diversity and expansion of the trans-sialidase gene family is a common feature in Trypanosoma cruzi clade members. Infect. Genet. Evol. 2016, 37, 266–274. [CrossRef] [PubMed]
51. Frasch, A.C. Functional diversity in the trans-sialidase and mucin families in Trypanosoma cruzi. Parasitol. Today 2000, 16, 282–286. [CrossRef]
52. Yoshida, N. Trypanosoma cruzi infection by oral route, how the interplay between parasite and host components modulate infectivity. Parasitol. Int. 2008, 57, 105–109. [CrossRef]
53. Freitas, L.M.; dos Santos, S.L.; Rodrigues-Luiz, G.F.; Mendes, T.A.; Rodrigues, T.S.; Gazzinelli, R.T.; Teixeira, S.M.; Fujitwara, R.T.; Bartholomeu, D.C. Genomic analyses, gene expression and antigenic profile of the trans-sialidase superfamily of Trypanosoma cruzi reveal an undetected level of complexity. PLoS ONE 2011, 6, e25914. [CrossRef] [PubMed]
54. Maeda, F.Y.; Clemente, T.M.; Macedo, S.; Cortez, C.; Yoshida, N. Host cell invasion and oral infection by Trypanosoma cruzi strains of genetic groups TcI and TcIV from chagasic patients. Parasites Vectors 2016, 9, 189. [CrossRef]
55. Azuaje, F.; Ramirez, J.L.; Da Silveira, J.F. In silico, biologically inspired modelling of genomic variation regions in the human protozoan parasite Trypanosoma cruzi. Front. Microbiol. 2016, 7, 2041. [CrossRef] [PubMed]
56. Reynaud, C.A.; Anquez, V.; Grimal, H.; Weill, J.C. A hyperconversion mechanism generates the chicken light chain preimmune repertoire. Cell 1997, 48, 379–388. [CrossRef]
57. Thon, G.; Balz, T.; Eisen, H. Antigenic diversity by the recombination of pseudogenes. Genes Dev. 1989, 3, 1247–1254. [CrossRef] [PubMed]
58. Allen, C.L.; Kelly, J.M. Trypanosoma cruzi: Mucin pseudogenes organized in a tandem array. Exp. Parasitol. 2001, 97, 173–177. [CrossRef] [PubMed]
59. Wen, Y.Z.; Zheng, L.L.; Qu, L.H.; Ayala, F.J.; Lun, Z.R. Pseudogenes are not pseudo any more. RNA Biol. 2012, 9, 27–32. [CrossRef] [PubMed]
60. Macías, F.; Afonso-Lehmann, R.; López, M.C.; Gómez, I.; Thomas, M.C. Biology of Trypanosoma cruzi Retrotransposons: From an Enzymatic to a Structural Point of View. Curr. Genom. 2018, 19, 110–118. [CrossRef] [PubMed]
61. Chiurillo, M.A.; Moraes Barros, R.R.; Souza, R.T.; Marini, M.M.; Antonio, C.R.; Cortez, D.R.; Curto, M.A.; Lorenz, H.A.; Schijman, A.G.; Ramirez, J.L.; et al. Subtelomeric I-SceI-Mediated Double-Strand Breaks Are Repaired by Homologous Recombination in Trypanosoma cruzi. Front. Microbiol. 2016, 7, 2041. [CrossRef] [PubMed]
62. Moraes Barros, R.R.; Marini, M.M.; António, C.R.; Cortez, D.R.; Miyake, A.M.; Lima, F.M.; Ruiz, J.C.; Bartholomeu, D.C.; Chiurillo, M.A.; Ramirez, J.L.; et al. Anatomy and evolution of telomeric and subtelomeric regions in the human protozoan parasite Trypanosoma cruzi. BMC Genom. 2012, 13, 229. [CrossRef]
63. Macías, F.; Afonso-Lehmann, R.; López, M.C.; Gómez, I.; Thomas, M.C. Biology of Trypanosoma cruzi Telomeres. Front. Cell. Infect. Microbiol. 2020, 9, 439. [CrossRef]
64. Ramirez, J.L. An Evolutionary View of Trypanosoma cruzi Telomeres. Front. Cell. Infect. Microbiol. 2020, 9, 439. [CrossRef]
65. Xing, J.; Wan, G.; Belancio, V.P.; Cordaux, R.; Deininger, P.L.; Batzer, M.A. Emergence of primate genes by retrotransposon mediated sequence transduction. PNAS 2006, 103, 17608–17613. [CrossRef] [PubMed]
66. Messenger, L.A.; Llewellyn, M.S.; Bhattacharyya, T.; Franzén, Ö.; Lewis, M.D.; Ramirez, J.D.; Carrasco, H.J.; Andersson, B.; Miles, M.A. Multiple mitochondrial Intergression events and heteroplasmy in Trypanosoma cruzi revealed by maxicircle MLST and next generation sequencing. PLoS Negl. Trop. Dis. 2012, 6, e1584. [CrossRef] [PubMed]
67. Rusman, F.; Floridia-Yapur, N.; Ragone, P.G.; Dioggue, P.; Tomasini, N. Evidence of hybridization, mitochondrial introgression and biparental inheritance of the KDNA minicircles in Trypanosoma cruzi I. PLoS Negl. Trop. Dis. 2020, 14, e0007770. [CrossRef] [PubMed]
68. Gaunt, M.; Yeo, M.; Frame, I.; Stothard, J.R.; Carrasco, H.J.; Taylor, M.C.; Mena, S.S.; Veazey, P.; Miles, G.A.; Acosta, N. Mechanism of genetic exchange in American trypanosomases. Nature 2003, 421, 936–939. [CrossRef] [PubMed]
69. Tsybayrenc, M.; Kjellberg, F.; Ayala, F.J. A clonal theory of parasitic protozoa: The population structures of Entamoeba, Giardia, Leishmania, Naegleria, Plasmodium, Trichomonas, and Trypanosoma and their medical and taxonomical consequences. PNAS 1990, 87, 2414–2418. [CrossRef]
70. Tibayrenc, M.; Ayala, F.J. Genomics and High-Resolution Typing Confirm Predominant Clonal Evolution Down to a Microevolutionary Scale in Trypanosoma cruzi. Pathogens 2020, 9, 356. [CrossRef]
71. Seo-Hidalgo, V.; De Pablos, L.M.; Osuna, A. Transcriptional and phenotypical heterogeneity of Trypanosoma cruzi cell populations. Open Biol. 2015, 5, 150190. [CrossRef]
72. Muñoz-Calderón, A.; Díaz-Bello, Z.; Ramírez, J.L.; Noya, O.; de Noya, B.A. Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela. J. Vector Borne Dis. 2019, 57. [CrossRef]
73. Muller, H.J. Some aspects of sex. *Am. Nat.* 1932, 703, 118–138. [CrossRef]
74. Garcia, J.B.; Rocha, J.P.; Costa-Silva, H.M.; Alves, C.L.; Machado, C.R.; Cruz, A.K. *Leishmania major* and *Trypanosoma cruzi* present distinct DNA damage responses. *Mol. Biochem. Parasitol.* 2016, 207, 23–32. [CrossRef]
75. Donelson, J. The promise of *T. cruzi* genomics. *Nature* 2010, 465, S16–S17.
76. Bartholomeu, D.C.; Buck, G.A.; Teixeira, S.M.R.; El-Sayed, N.M.A. Genetics of *Trypanosoma cruzi* Nuclear Genome. In *American Trypanosomiasis Chagas Disease Chagas Disease One Hundred Years of Research*; Telleria, J., Tybayrenc, M., Eds.; Elsevier: Amsterdam, The Netherlands, 2010; pp. 433–448. ISBN 9780128010693.
77. Menezes, C.; Carneiro Costa, G.; Gollob, K.J.; Dutra, W.O. Clinical aspects of Chagas disease and implications for novel therapies. *Drug Dev. Res.* 2011, 72, 471–479. [CrossRef] [PubMed]
78. Soares Medeiros, L.C.; South, L.; Peng, D.; Bustamante, J.M.; Wang, W.; Bunkofske, M.; Perumal, N.; Sanchez-Valdez, F.; Tarleton, R.L. Rapid, Selection-Free, High-Efficiency Genome Editing in Protozoan Parasites Using CRISPR-Cas9 Ribonucleoproteins. *mBio* 2017, 8, e01788-17. [CrossRef]
79. Lander, N.; Li, Z.H.; Niyogi, S.; Docampo, R. CRISPR/Cas9-Induced Disruption of Paraflagellar Rod Protein 1 and 2 Genes in *Trypanosoma cruzi* Reveals Their Role in Flagellar Attachment. *mBio* 2015, 6, e01012-15. [CrossRef] [PubMed]

© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).